The impact of obesity and disease on busulfan oral clearance in adults

Blood

Volumn 93, Issue 12, 1999, Pages 4436-4440

  Gibbs, John P ^b   Gooley, Ted ^b   Corneau, Bruce ^b   Murray, Georgia ^b   Stewart, Patricia ^b   Appelbaum, Frederick R ^b   Slattery, John T ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN;

ADULT; ARTICLE; BODY MASS; BODY SIZE; BODY WEIGHT; CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0033564364     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.12.4436.412k16_4436_4440     Document Type: Article

References (21)

1. Grochow LB: Busulfan disposition: The role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 20:18, 1993
2. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, York RC, Lin LS, Devine SM, Geller RB, Heffner LT, Hillyer CD, Holland HK, Winton EF, Saral R: Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 17:225, 1996
3. Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, Anasetti C, Bensinger WI, Fisher LD, Appelbaum FR, Hansen JA: Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 16:31, 1995
4. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, Soil E, Anasetti C, Bowden R, Bryant E, Chauncey T, Deeg HJ, Doney KC, Flowers M, Gooley T, Hansen JA, Martin PJ, McDonald GB, Nash R, Petersdorf EW, Sanders JE, Schoch G, Stewart P, Storb R, Sullivan KM, Thomas ED, Witherspoon RP, Appelbaum FR: Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation. Blood 89:3055, 1997
5. Rowland M, Tozer TN: Age and Weight: Clinical pharmacokinetics: Concepts and applications. Philadelphia, PA, Williams and Wilkins, 1995, p 233
6. Vassal G, Fischer A, Challine D, Boland I, Ledheist F, Lemerle S, Vilmer E, Rahimy C, Souillet G, Gluckman E, Michel G, Deroussent A, Gouyette A: Busulfan disposition below the age of three: Alteration in children with lysosomal storage disease. Blood 82:1030, 1993
7. Hassan M, Fasth A, Gerritsen B, Haraldsson A, Syrackov'a Z, van den Berg H, Sandstrom M, Karlsson M, Kumlien S, Vossen J: Busulfan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant 18:843, 1996
8. Gibbs JP, Czerwinski M, Slattery JT: Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res 56:3678, 1996
9. Czerwinski M, Gibbs JP, Slattery JT: Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos 24:1015, 1996
10. Hassan M, Oberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B, Totterman T, Eksborg S, Simonsson B: Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 36:525, 1989
11. Hassan M, Ehrsson H, Ljungman P: Aspects concerning busulfan pharmacokinetics and bioavailability. Leuk Lymphoma 22:395, 1996
12. Abernethy DR, Todd EL, Schwartz JB: Caffeine disposition in obesity. Br J Clin Pharmacol 20:61, 1995
13. Kamimori GH: The effect of obesity and exercise on the pharmacokinetics of caffeine in lean and obese volunteers. Eur J Clin Pharmacol 31:595, 1987
14. Abernethy DR, Greenblatt DJ, Divoll M, Shader RI: Prolongation of drug half-life due to obestiy: studies of des-methyldiazepam (clorazepate). J Pharm Sci 71:942, 1982
15. Abernethy DR, Greenblatt DJ: Phenytoin disposition in obesity, determination of a loading dose. Arch Neurol 42:468, 1985
16. Caraco Y, Zylber-Katz E, Berry EM, Levy M: Carbamazepine disposition in obesity. Clin Pharmacol Ther 51:133, 1992
17. Caraco Y, Zylber-Katz E, Berry EM, Levy M: Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. Eur J Clin Pharmacol 47:525, 1995
18. Abernethy DR: Obesity, sex and acetominophen disposition. Clin Pharmacol Ther 31:783, 1982
19. Milsap RL, Plaisance KI, Jusko WJ: Prednisolone disposition in obese men. Clin Pharmacol Ther 36:824, 1984
20. Abernethy DR, Greenblatt DJ: Ibuprofen disposition in obese individuals. Arthritis Rheum 28:1117, 1985
21. Abernethy DR, Greenblatt DJ: Drug disoposition in obese humans: An update. Clin Pharmacokinet 11:199, 1986